Alimera Sciences Overview

  • Founded
  • 2003
Founded
  • Status
  • Public
  • Employees
  • 127
Employees
  • Stock Symbol
  • ALIM
Stock Symbol
  • Share Price
  • $4.20
  • (As of Thursday Closing)

Alimera Sciences General Information

Description

Alimera Sciences Inc is a pharmaceutical company. It specializes in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration, and retinal vein occlusion. The product portfolio of the company includes ILUVIEN, which is developed to treat diabetic macular edema. In addition, to the activities related to the development of ILUVIEN, the group is also researching the safety and effectiveness of NADPH (Nicotinamide Adenine Dinucleotide Phosphate) oxidase inhibitors. Geographically it operates through the region of US and also it has its presence in the international market.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Biotechnology
Stock Exchange
NAS
Primary Office
  • 6120 Windward Parkway
  • Suite 290
  • Alpharetta, GA 30005
  • United States
+1 (678) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Alimera Sciences Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$4.20 $4.20 $21.1M 5.03M 43.1K -$1.27

Alimera Sciences Financials Summary

In Thousands,
USD
TTM 30-Jun-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018 FY 2017 31-Dec-2017
EV 91,537 99,403 106,341 169,540
Revenue 54,771 53,943 46,599 35,912
EBITDA 1,268 (2,717) (8,856) (13,575)
Net Income (6,386) (10,443) (16,382) (22,001)
Total Assets 49,094 50,309 54,108 59,924
Total Debt 43,936 39,476 38,414 34,752
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Alimera Sciences Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Alimera Sciences‘s full profile, request access.

Request a free trial

Alimera Sciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Alimera Sciences‘s full profile, request access.

Request a free trial

Alimera Sciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Alimera Sciences Inc is a pharmaceutical company. It specializes in the research, development, and commercialization of
Pharmaceuticals
Alpharetta, GA
127 As of 2019
00000
000000 - 000 00000

00000000

m dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore
0000000000000
Trevose, PA
00 As of 0000
00000
0000 0000-00-00
00000000000 00000

00000000

prehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat
0000000000000
Watertown, MA
00 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Alimera Sciences Competitors (42)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Strongbridge Biopharma Corporate Backed or Acquired Trevose, PA 00 00000 00000000000 00000
00000000 000000000 Corporation Watertown, MA 00 00000 000000000 00000
00000000 Formerly VC-backed South San Francisco, CA 00 00000 0000000000.
000000 00000000 Formerly VC-backed Foster City, CA 00000 00.000 0&0
00000 000000000000 Formerly VC-backed Durham, NC 000 00000 000000 - 000 00000
You’re viewing 5 of 42 competitors. Get the full list »

Alimera Sciences Executive Team (15)

Name Title Board Seat Contact Info
Richard Eiswirth Jr. Chief Executive Officer & Board Member
Philip Jones Chief Financial Officer
Philip Ashman Ph.D Chief Operating Officer, Operations & Senior Vice President
David Holland Chief Marketing Officer, Marketing & Founder
Philip Haldar Vice President & European Marketing Director
You’re viewing 5 of 15 executive team members. Get the full list »

Alimera Sciences Board Members (18)

Name Representing Role Since
Calvin Roberts MD Self Board Member 000 0000
Garheng Kong Ph.D Self Board Member 000 0000
James Largent Alimera Sciences Board Member 000 0000
John Snisarenko Self Board Member 000 0000
Mark Brooks Self Board Member 000 0000
You’re viewing 5 of 18 board members. Get the full list »

Alimera Sciences Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Alimera Sciences Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Alimera Sciences‘s full profile, request access.

Request a free trial